Johnson & Johnson Completes the Acquisition of V-Wave
Shots:
- Johnson & Johnson has successfully completed the acquisition V-Wave with aim to establish leadership in the cardiovascular segment to tackle heart failure
- Under US GAAP, this transaction will be treated as an asset acquisition, leading in-process R&D charge of about $600M in Q4’24. J&J projects a diluted adjusted EPS impact of roughly $0.24 in 2024 and ~$0.06 in 2025. Full-year financial outlook will be presented on Oct 15, 2024
- Now V-wave will to be part of J&J’s Medtech cardiovascular segment, where Ventura Interatrial Shunt an innovative implantable device, which holds great potential for heart failure with reduced ejection fraction (HFrEF) patients
Ref: Johnson & Johnson | Image: V-Wave
Related News: Johnson and Johnson to Acquire V-Wave, Expanding and Strengthening J&J MedTech Segment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
